26993-39-5

Basic information

• Product Name: (2S,3R,4E)-2-amino-3-hydroxyoctadec-4-en-1-yl dihydrogen phosphate
• Synonyms: (2S,3R,4E)-2-Amino-3-hydroxyoctadec-4-en-1-yl dihydrogen phosphate; (2S,3R,4E)-2-ammonio-3-hydroxyoctadec-4-en-1-yl hydrogen phosphate; 4-Octadecene-1,3-diol, 2-amino-, 1-(dihydrogen phosphate), (2S,3R,4E)-; 4-Octadecene-1,3-diol, 2-amino-, 1-(dihydrogen phosphate), (4E)-
• CAS NO: 26993-39-5
• Molecular Formula: C₁₈H₃₈NO₅P
• Molecular Weight: 379.4718
• Mol File: 26993-39-5.mol
• Article Data: 19

Chemical Properties

• Boiling Point: 548.8°C at 760 mmHg
• Flash Point: 285.7°C
• Density: 1.094g/cm³
• Vapor Pressure: 2.49E-14mmHg at 25°C
• Refractive Index: 1.501
• CAS DataBase Reference: (2S,3R,4E)-2-amino-3-hydroxyoctadec-4-en-1-yl dihydrogen phosphate(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,3R,4E)-2-amino-3-hydroxyoctadec-4-en-1-yl dihydrogen phosphate(26993-39-5)
• EPA Substance Registry System: (2S,3R,4E)-2-amino-3-hydroxyoctadec-4-en-1-yl dihydrogen phosphate(26993-39-5)

Safety Data

• Hazardous Substances Data: 26993-39-5(Hazardous Substances Data)

Upstream product

• 149035-79-0 <(2S,3R,4E)-2-amino-3-(tert-butyldimethylsilyloxy)-4-octadecene-1-yl> dihydrogen phosphate 
• 207516-11-8 Phosphoric acid (E)-(2S,3R)-2-amino-3-hydroxy-octadec-4-enyl ester bis-[1-(2-nitro-phenyl)-ethyl] ester 
• 312933-38-3 tert-butyl ((2S,3R,E)-1-((dimethoxyphosphoryl)oxy)-3-hydroxyoctadec-4-en-2-yl)carbamate 
• 116467-63-1 N-tert-butyloxycarbonylsphingosine 
• 123-78-4 (2S,3R,4E)-2-amino-4-octadecene-1,3-diol 
• 207516-23-2 tert-butyl (4S,5R,1'E)-4-(hydroxymethyl)-2,2-dimethyl-5-(pentadec-1'-enyl)-oxazolidine-3-carboxylate 
• 207516-20-9 Benzoic acid (E)-(2S,3R)-2-tert-butoxycarbonylamino-3-hydroxy-octadec-4-enyl ester 
• 207516-26-5 (4S,5R)-4-{Bis-[1-(2-nitro-phenyl)-ethoxy]-phosphoryloxymethyl}-2,2-dimethyl-5-((E)-pentadec-1-enyl)-oxazolidine-3-carboxylic acid tert-butyl ester 
• 114299-64-8 (2S,3S,4E)-2-azido-3-O-(tert-butyldimethylsilyl)-4-octadecen-1,3-diol 
• 137905-29-4 (2S,3R,4E)-2-amino-3-(tert-butyldimethylsilyloxy)-4-octadecene-1-ol 
• 149035-77-8 (2S,3R,4E)-3-(tert-butyldimethylsilyloxy)-2-(9-fluorenylmethyloxycarbonylamino)-4-octadecene-1-ol 
• 149035-78-9 <(2S,3R,4E)-3-(tert-butyldimethylsilyloxy)-2-(9-fluorenylmethyloxycarbonylamino)-4-octadecene-1-yl> bis(2-cyanoethyl) phosphate 
• 860021-47-2 (2S,3R)-2-amino-octadec-4-ene-3-(t-butyl-diphenylsilyloxy)-1-ol-phosphate 

Relevant articles and documents

4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO

Disclosed are halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections. Such viral infections can include tongaviridae, bunyaviridae, arenaviridae, coronaviridae, flaviviridae, picornaviridae, Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infections.

NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO

This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.

Studies on the inhibition of sphingosine-1-phosphate lyase by stabilized reaction intermediates and stereodefined azido phosphates

Two kinds of inhibitors of the PLP-dependent enzyme sphingosine-1-phosphate lyase have been designed and tested on the bacterial (StS1PL) and the human (hS1PL) enzymes. Amino phosphates 1, 12, and 32, mimicking the intermediate aldimines of the catalytic process, were weak inhibitors on both enzyme sources. On the other hand, a series of stereodefined azido phosphates, resulting from the replacement of the amino group of the natural substrates with an azido group, afforded competitive inhibitors in the low micromolar range on both enzyme sources. This similar behavior represents an experimental evidence of the reported structural similarities for both enzymes at their active site level. Interestingly, the anti-isomers of the non-natural enantiomeric series where the most potent inhibitors on hS1PL.